Delivered as an educational lecture to the Hawaii State Department of Health’s Office of Medical Cannabis Control and Regulation, this comprehensive guide replaces commercial marketing myths with rigorous clinical endocannabinology. Dr. Benjamin Caplan breaks down why universal starting dosages like ‘5mg’ fail diverse patient populations, how first-pass hepatic metabolism transforms delta-9-THC into the significantly more potent 11-hydroxy-THC, and how individual genetics, hormones, and cytochrome P450 enzymes dictate therapeutic outcomes. Designed for healthcare providers, regulators, and patients alike, this reference establishes an evidence-based foundation for understanding how cannabinoids interact with the human body.